Idexx Laboratories, Inc. · NASDAQ:IDXX
Idexx Laboratories — Q4 2025 Earnings Presentation
5 slides from Idexx Laboratories's earnings presentation, Feb 2, 2026
Slide 1: IDEXX Q4 & Full Year 2025 Earnings Highlights
IDEXX Q4 & Full Year 2025 Earnings Highlights (NASDAQ: IDXX) Operating Diluted Revenue Profit Earnings Per Share Q4 $1,091M $316M $3.08 Reported growth: +14% 29% of Revenue Organic growth: +12% Reported growth: +18% YoY change in basis points: CAG Diagnostics Recurring Reported +150 Comparable growt
Slide 2: 2026 Growth and Financial Performance Outlook Commentary
IDEXX Q4 & Full Year 2025 Earnings Highlights (NASDAQ: IDXX) 2026 Growth and Financial Performance Outlook Commentary • Provides initial outlook for 2026 revenue guidance range of $4,632 million - $4,720 million, reflecting growth of 7.6% - 9.6% reported and 7.0% - 9.0% organic, led by CAG Diagnosti
Slide 3: U.S. Companion Animal Sector Growth Update
U.S. Companion Animal Sector Growth Update As of December 31, 2025 Total Practice Revenue and Visit Growth Weighted Average Year-over-Year % Change Per Practice* 20% 15% 10% i Practice Revenue 5% 5.3% 2.1% 2.0% 1.8% 3.0% 2.4% 0% Total Visits 5% Eo 2.6% 3.1% 3.1% 2.8% Qi Q2 Q3 Q4 Qi Q2 Q3 Q4 Ql Q2 Q3
Slide 4: U.S. Companion Animal Sector Growth Update
U.S. Companion Animal Sector Growth Update As of December 31, 2025 Contributors to U.S. Companion Animal Diagnostic Revenue Growth per Practice** + 6.5% Q4’2025 Year-Over-Year Growth (%) - 1.5% + 1.0% + 6.5% +4.0% Q4’2024 - 2.5% 0.0% Q4 Average + 0.5% + 0.5% Le — SC Clinical Visit ‘Diagnostic ‘Diagn
Slide 5: U.S. Companion Animal Sector Growth Update
U.S. Companion Animal Sector Growth Update As of December 31, 2025 Contributors to U.S. Companion Animal Diagnostic Revenue Growth per Practice** FYi2025 Year-Over-Year Growth (%) - 2.0% 6.5% + 5.5% + 1.0% FY’2024 + 6.5% +4.5% - 2.0% 0.0% + 7.5% + 10.0% FY Average + 2.0% +0.5% | Clinical Visit ‘Diag